Cell-lineage regulated myogenesis for dystrophin replacement

A novel therapeutic approach for treatment of muscular dystrophy

En Kimura, Jay J. Han, Sheng Li, Brent Fall, Jennifer Ra, Miki Haraguchi, Stephen J. Tapscott, Jeffrey S. Chamberlain

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Duchenne muscular dystrophy (DMD) is characterized in skeletal muscle by cycles of myofiber necrosis and regeneration leading to loss of muscle fibers and replacement with fibrotic connective and adipose tissue. The ongoing activation and recruitment of muscle satellite cells for myofiber regeneration results in loss of regenerative capacity in part due to proliferative senescence. We explored a method whereby new myoblasts could be generated in dystrophic muscles by transplantation of primary fibroblasts engineered to express a micro-dystrophin/enhanced green fluorescent protein (μDys/eGFP) fusion gene together with a tamoxifen-inducible form of the myogenic regulator MyoD [MyoD-ER(T)]. Fibroblasts isolated from mdx4cv mice, a mouse model for DMD, were efficiently transduced with lentiviral vectors expressing μDys/ eGFP and MyoD-ER(T) and underwent myogenic conversion when exposed to tamoxifen. These cells could also be induced to differentiate into μDys/eGFP-expressing myocytes and myotubes. Transplantation of transduced mdx4cv fibroblasts into mdx4cv muscles enabled tamoxifen-dependent regeneration of myofibers that express μDys. This lineage control method therefore allows replenishment of myogenic stem cells using autologous fibroblasts carrying an exogenous dystrophin gene. This strategy carries several potential advantages over conventional myoblast transplantation methods including: (i) the relative simplicity of culturing fibroblasts compared with myoblasts, (ii) a readily available cell source and ease of expansion and (iii) the ability to induce MyoD gene expression in vivo via administration of a medication. Our study provides a proof of concept for a novel gene/stem cell therapy technique and opens another potential therapeutic approach for degenerative muscle disorders.

Original languageEnglish (US)
Pages (from-to)2507-2517
Number of pages11
JournalHuman Molecular Genetics
Volume17
Issue number16
DOIs
StatePublished - Aug 2008
Externally publishedYes

Fingerprint

Dystrophin
Muscle Development
Muscular Dystrophies
Cell Lineage
Fibroblasts
Myoblasts
Tamoxifen
Regeneration
Duchenne Muscular Dystrophy
Transplantation
Muscles
Muscle Cells
Stem Cells
Therapeutics
Gene Fusion
Skeletal Muscle Fibers
Muscular Diseases
Cell- and Tissue-Based Therapy
Connective Tissue
Genes

ASJC Scopus subject areas

  • Genetics

Cite this

Cell-lineage regulated myogenesis for dystrophin replacement : A novel therapeutic approach for treatment of muscular dystrophy. / Kimura, En; Han, Jay J.; Li, Sheng; Fall, Brent; Ra, Jennifer; Haraguchi, Miki; Tapscott, Stephen J.; Chamberlain, Jeffrey S.

In: Human Molecular Genetics, Vol. 17, No. 16, 08.2008, p. 2507-2517.

Research output: Contribution to journalArticle

Kimura, E, Han, JJ, Li, S, Fall, B, Ra, J, Haraguchi, M, Tapscott, SJ & Chamberlain, JS 2008, 'Cell-lineage regulated myogenesis for dystrophin replacement: A novel therapeutic approach for treatment of muscular dystrophy', Human Molecular Genetics, vol. 17, no. 16, pp. 2507-2517. https://doi.org/10.1093/hmg/ddn151
Kimura, En ; Han, Jay J. ; Li, Sheng ; Fall, Brent ; Ra, Jennifer ; Haraguchi, Miki ; Tapscott, Stephen J. ; Chamberlain, Jeffrey S. / Cell-lineage regulated myogenesis for dystrophin replacement : A novel therapeutic approach for treatment of muscular dystrophy. In: Human Molecular Genetics. 2008 ; Vol. 17, No. 16. pp. 2507-2517.
@article{78280d47ae094e8b95030d7b9a815528,
title = "Cell-lineage regulated myogenesis for dystrophin replacement: A novel therapeutic approach for treatment of muscular dystrophy",
abstract = "Duchenne muscular dystrophy (DMD) is characterized in skeletal muscle by cycles of myofiber necrosis and regeneration leading to loss of muscle fibers and replacement with fibrotic connective and adipose tissue. The ongoing activation and recruitment of muscle satellite cells for myofiber regeneration results in loss of regenerative capacity in part due to proliferative senescence. We explored a method whereby new myoblasts could be generated in dystrophic muscles by transplantation of primary fibroblasts engineered to express a micro-dystrophin/enhanced green fluorescent protein (μDys/eGFP) fusion gene together with a tamoxifen-inducible form of the myogenic regulator MyoD [MyoD-ER(T)]. Fibroblasts isolated from mdx4cv mice, a mouse model for DMD, were efficiently transduced with lentiviral vectors expressing μDys/ eGFP and MyoD-ER(T) and underwent myogenic conversion when exposed to tamoxifen. These cells could also be induced to differentiate into μDys/eGFP-expressing myocytes and myotubes. Transplantation of transduced mdx4cv fibroblasts into mdx4cv muscles enabled tamoxifen-dependent regeneration of myofibers that express μDys. This lineage control method therefore allows replenishment of myogenic stem cells using autologous fibroblasts carrying an exogenous dystrophin gene. This strategy carries several potential advantages over conventional myoblast transplantation methods including: (i) the relative simplicity of culturing fibroblasts compared with myoblasts, (ii) a readily available cell source and ease of expansion and (iii) the ability to induce MyoD gene expression in vivo via administration of a medication. Our study provides a proof of concept for a novel gene/stem cell therapy technique and opens another potential therapeutic approach for degenerative muscle disorders.",
author = "En Kimura and Han, {Jay J.} and Sheng Li and Brent Fall and Jennifer Ra and Miki Haraguchi and Tapscott, {Stephen J.} and Chamberlain, {Jeffrey S.}",
year = "2008",
month = "8",
doi = "10.1093/hmg/ddn151",
language = "English (US)",
volume = "17",
pages = "2507--2517",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Cell-lineage regulated myogenesis for dystrophin replacement

T2 - A novel therapeutic approach for treatment of muscular dystrophy

AU - Kimura, En

AU - Han, Jay J.

AU - Li, Sheng

AU - Fall, Brent

AU - Ra, Jennifer

AU - Haraguchi, Miki

AU - Tapscott, Stephen J.

AU - Chamberlain, Jeffrey S.

PY - 2008/8

Y1 - 2008/8

N2 - Duchenne muscular dystrophy (DMD) is characterized in skeletal muscle by cycles of myofiber necrosis and regeneration leading to loss of muscle fibers and replacement with fibrotic connective and adipose tissue. The ongoing activation and recruitment of muscle satellite cells for myofiber regeneration results in loss of regenerative capacity in part due to proliferative senescence. We explored a method whereby new myoblasts could be generated in dystrophic muscles by transplantation of primary fibroblasts engineered to express a micro-dystrophin/enhanced green fluorescent protein (μDys/eGFP) fusion gene together with a tamoxifen-inducible form of the myogenic regulator MyoD [MyoD-ER(T)]. Fibroblasts isolated from mdx4cv mice, a mouse model for DMD, were efficiently transduced with lentiviral vectors expressing μDys/ eGFP and MyoD-ER(T) and underwent myogenic conversion when exposed to tamoxifen. These cells could also be induced to differentiate into μDys/eGFP-expressing myocytes and myotubes. Transplantation of transduced mdx4cv fibroblasts into mdx4cv muscles enabled tamoxifen-dependent regeneration of myofibers that express μDys. This lineage control method therefore allows replenishment of myogenic stem cells using autologous fibroblasts carrying an exogenous dystrophin gene. This strategy carries several potential advantages over conventional myoblast transplantation methods including: (i) the relative simplicity of culturing fibroblasts compared with myoblasts, (ii) a readily available cell source and ease of expansion and (iii) the ability to induce MyoD gene expression in vivo via administration of a medication. Our study provides a proof of concept for a novel gene/stem cell therapy technique and opens another potential therapeutic approach for degenerative muscle disorders.

AB - Duchenne muscular dystrophy (DMD) is characterized in skeletal muscle by cycles of myofiber necrosis and regeneration leading to loss of muscle fibers and replacement with fibrotic connective and adipose tissue. The ongoing activation and recruitment of muscle satellite cells for myofiber regeneration results in loss of regenerative capacity in part due to proliferative senescence. We explored a method whereby new myoblasts could be generated in dystrophic muscles by transplantation of primary fibroblasts engineered to express a micro-dystrophin/enhanced green fluorescent protein (μDys/eGFP) fusion gene together with a tamoxifen-inducible form of the myogenic regulator MyoD [MyoD-ER(T)]. Fibroblasts isolated from mdx4cv mice, a mouse model for DMD, were efficiently transduced with lentiviral vectors expressing μDys/ eGFP and MyoD-ER(T) and underwent myogenic conversion when exposed to tamoxifen. These cells could also be induced to differentiate into μDys/eGFP-expressing myocytes and myotubes. Transplantation of transduced mdx4cv fibroblasts into mdx4cv muscles enabled tamoxifen-dependent regeneration of myofibers that express μDys. This lineage control method therefore allows replenishment of myogenic stem cells using autologous fibroblasts carrying an exogenous dystrophin gene. This strategy carries several potential advantages over conventional myoblast transplantation methods including: (i) the relative simplicity of culturing fibroblasts compared with myoblasts, (ii) a readily available cell source and ease of expansion and (iii) the ability to induce MyoD gene expression in vivo via administration of a medication. Our study provides a proof of concept for a novel gene/stem cell therapy technique and opens another potential therapeutic approach for degenerative muscle disorders.

UR - http://www.scopus.com/inward/record.url?scp=48249119884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249119884&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddn151

DO - 10.1093/hmg/ddn151

M3 - Article

VL - 17

SP - 2507

EP - 2517

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 16

ER -